Celldex Therapeutics, Inc. (CLDX) Q1 2017 Earnings Results

Celldex Therapeutics Misses on EPS, Stock Up 3.27%

Celldex Therapeutics reported a loss per share of $0.28, but the stock reacted positively, rising by 3.27%. Investors may be encouraged by the company's focus on clinical programs despite the lack of revenue details and guidance. The stock's increase suggests some optimism about future developments.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.28	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Neutral

Management emphasized their commitment to ongoing clinical trials and research. However, they did not provide any updates on future guidance.

Management did not provide specific guidance for future quarters.

The company remains focused on advancing its clinical programs.

Celldex Therapeutics Misses on EPS, Stock Up 3.27%

Key numbers

Management commentary

Celldex Therapeutics, Inc.

More earnings this week

Celldex Therapeutics Misses on EPS, Stock Up 3.27%

Key numbers

Management commentary